Blinatumomab consolidation for high-risk Ph− B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST studyNicolas Boissel, Hervé Dombret, F. Huguet et al.|Blood|2026Cited by 2
IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy responseSonja Bendig, Lorenz Bastian, Rathana Kim et al.|Blood|2026Cited by 0